Lyka Labs receives product permission for Tofacitinib Ointment

Lyka Labs has announced a significant development as it receives product permission from the Central Drugs Standard Control Organization of India. The permission is for the manufacture and marketing of Tofacitinib Ointment 2% w/w.

 

This regulatory milestone comes after Lyka Labs successfully completed a clinical trial involving 125 patients across 8 Clinical Trial Centers within India. The product permission signifies a significant step for the company, expanding its portfolio and potentially offering valuable solutions in the pharmaceutical market.

 

Stay tuned for further updates from Lyka Labs as it progresses with the launch and marketing of Tofacitinib Ointment 2% w/w.

Top stories
Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read . 02 Aug 2024 . 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read . 02 Aug 2024 . 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read . 02 Aug 2024 . 12:36 PM

Related Blogs
blog-logo

Share Market

blog-logo

14 mins read . 06 Dec 2024

Stocks Under 1000 Rupees in India

  • 0 people read
blog-logo

Economy

blog-logo

8 mins read . 05 Dec 2024

History of Reliance Group

  • 0 people read
Kickstart your equities journey today You've got this
By submitting this I agree to the terms & conditions